Hepatocellular carcinoma: a global view

By J. D. Yang, Lewis R. Roberts. Nature Reviews Gastroenterology &Hepatology, 2010

1,309 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/6d5d8829a2e1bd29b532ef35dc25e04ab2f49fc3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Lewis R. Roberts
2. M. Kudo
3. J. D. Yang

In Hepatology

1. Lewis R. Roberts
2. M. Kudo
3. A. Cheng
4. J. D. Yang

Citations in the corpus

• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “The highest age-adjusted incidence rates ([20/100,000) are recorded in East Asia (North and South Korea, China, and Vietnam) and sub-Saharan Africa [8].”
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2011, background): “Patients diagnosed with HCC have a 33% probability of death during the first year [12,13].”
• Epidemiology and Management of Hepatocellular Carcinoma (2010, background): “TACE is a dual treatment process that includes (1) intraarterial delivery of chemotherapeutic agent(s) directly into the tumor, and (2) embolization of the hepatic artery that feeds the tumor.”
• Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017, neutral): “In developed nations, there has been a rise in HCC incidence partly attributed to HCV, obesity, and diabetes (Yang and Roberts, 2010).”